Hypertrophic And Keloid Scar Treatment Market Scope And Analysis

Report Code : TIPRE00007237
Category : Life Sciences

No. of Pages : 150

Buy Now

Hypertrophic and Keloid Scar Treatment Market Analysis and Scope (2024 to 2031)

Buy Now

Hypertrophic and Keloid Scar Treatment Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 5.32 Billion
Market Size by 2031	US$ 15.18 Billion
Global CAGR (2023 - 2031)	11.4%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Scar Type Hypertrophic Keloid By Product Type Laser Products Topical Products Injectables Other Products By End User Hospitals Clinics Homecare
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Alliance Pharma PLC M lnlycke Health Care AB Smith Nephew Newmedical Technology Inc Rej vaskin Sonoma Pharmaceuticals Inc Suneva Medical HRA Pharma Lumenis Perrigo Company plc

Hypertrophic and Keloid Scar Treatment Market News and Recent Developments

The hypertrophic and keloid scar treatment market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for hypertrophic and keloid scar treatment and strategies:

AVITA Medical, Inc. received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to market the RECELL System in the country. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, to treat severe burns, while significantly reducing the amount of donor skin required. The system is designed to be used at the point of care alone or in combination with autografts, depending on the depth of the burn injury. (Source: AVITA Medical Inc., Press Release, 2022)
OliX Pharmaceuticals, Inc. completed patient enrollment in the Phase 2a clinical trial of OLX101A, an investigational therapeutic program for treating hypertrophic scar. In October 2020, the Company received FDA clearance to advance the investigation of OLX10010 (compound name of OLX101A) and began enrolling patients for the Phase 2a clinical trial across five sites in the US. The study is conducted to evaluate the effectiveness of OLX10010 in reducing the recurrence of hypertrophic scars after scar revision surgery. (Source: OliX Pharmaceuticals, Inc., Press Release, 2022)

Hypertrophic and Keloid Scar Treatment Market Report Coverage and Deliverables

The “Hypertrophic and Keloid Scar Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles